Analysts See $-0.77 EPS for Leap Therapeutics, Inc. (LPTX)

January 20, 2018 - By Louis Casey

 Analysts See $ 0.77 EPS for Leap Therapeutics, Inc. (LPTX)

Analysts expect Leap Therapeutics, Inc. (NASDAQ:LPTX) to report $-0.77 EPS on February, 12.After having $-0.73 EPS previously, Leap Therapeutics, Inc.’s analysts see 5.48 % EPS growth. The stock decreased 0.81% or $0.05 during the last trading session, reaching $6.16. About 11,205 shares traded. Leap Therapeutics, Inc. (NASDAQ:LPTX) has 0.00% since January 20, 2017 and is . It has underperformed by 16.70% the S&P500.

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapeutics in cancer biology. The company has market cap of $76.10 million. The Company’s clinical stage programs include DKN-01, a monoclonal antibody targeting Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric and biliary tract cancers, as well as in Phase I clinical trial in patients with non-small cell lung cancer; and TRX518, a monoclonal antibody that is in Phase I clinical trial targeting the glucocorticoid-induced tumor necrosis factor-related receptor in patients with solid tumors. It currently has negative earnings. Leap Therapeutics, Inc. has a clinical trial collaboration agreement with Merck & Co., Inc. to investigate Leap??s DKK1 antagonist, DKN-01, in combination with Merck??s anti-PD-1 therapy, KEYTRUDA, in patients with relapsed or refractory advanced esophagogastric cancers.

More notable recent Leap Therapeutics, Inc. (NASDAQ:LPTX) news were published by: Globenewswire.com which released: “Leap Therapeutics Reports Third Quarter 2017 Financial Results and Announces …” on November 13, 2017, also Streetinsider.com with their article: “Form 8-K LEAP THERAPEUTICS, INC. For: Jan 12” published on January 17, 2018, Marketwatch.com published: “Leap Therapeutics Inc.” on January 23, 2017. More interesting news about Leap Therapeutics, Inc. (NASDAQ:LPTX) were released by: Globenewswire.com and their article: “Leap Therapeutics Announces Collaboration With EORTC to Evaluate DKN-01 in …” published on September 08, 2017 as well as Globenewswire.com‘s news article titled: “Leap Therapeutics Announces $18 Million Private Placement Offering” with publication date: November 15, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.